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There has been an increased interest in beta therapeutic nuclear medicine, which emits relatively high-
energy (>1 MeV) b-rays and the production in vivo of Bremsstrahlung sufﬁcient for external imaging, the
produced Bremsstrahlung radiation hazard warrants evaluation. The Bremsstrahlung dose from patient
administered b-ray emitted radionuclide has been calculated by extending the national council on
Radiation Protection and measurement model of a point source in air to account for biologic elimination
of activity. We have estimated the probability of bremsstrahlung production, speciﬁc Bremsstrahlung
constant (deﬁned by Zanzonico et al.) and activity (Arelease) in bone cortical, bone compact, different
regions of tooth enamel (enamel dentin junction (EDJ), enamel middle surface, enamel inner surface),
different regions of dentin (outer surface, middle surface, enamel dentin junction (EDJ)), soft tissue, lungs
and skeleton for different therapeutic beta-emitting radionuclide. In the present calculations we have
used modiﬁed atomic number (Zmod) deﬁned for bremsstrahlung process.
Proper localization and quantiﬁcation of incorporated beta emitters in bone and tooth are possible,
because Bremsstrahlung production is greater in bone and tooth than soft tissue due to their high
modiﬁed atomic number (Zmod). Radionuclide therapy with pure b-ray emitters emitted in bone, tooth,
soft tissue, lungs and skeleton does not require medical conﬁnement of patients for radiation protection.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
With an increasing interest in therapeutic nuclear medicine,
application of incorporated beta-emitting nuclides has been
observed to have extremely high potential in treatment of both
malignant and non-malignant conditions. In malignant conditions
tumour speciﬁc metabolic and biological characteristics are effec-
tively deployed to optimize the targeting of radionuclides and
hence permit the successful therapy. A therapeutic radionuclide
should emit principally non-penetrating radiations (i.e., particles
such as b-rays) to maximize self-irradiation of the target region and
minimize irradiation of non-target regions. Increasingly, pure b-ray
emitters (Table 1) are being considered and used as therapeutic
radionuclides (Webber et al., 1989; Fritzberg and Wessels, 1995).
In the instances where beta-emitting radionuclides are used for
therapy of non-malignant conditions, the speciﬁc area of current
interest relates to application of radionuclides in radiosynovictomy.
This includes the treatment of subtle painful conditions associated
with disease of joints such as rheumatoid arthritis or villonodular
synovitis (Franssen et al., 1989; Vont Pad Bosch et al., 1981). Beta-
emitting nuclides such as 90Y, 32P, 165D etc. offer clinically proven. Manjunatha).
All rights reserved.and cost effective alternative to surgical synovictomy (Rodrigues-
Merchan et al., 1997; Lofquist et al., 1997).
Uchiyama et al. (1997) reported that Strontium-89 chloride is
being widely used as a palliative treatment for patients with bone
pain caused by bone metastases. A Zeeman atomic absorption
spectrometry study shows that some extent of strontium also
presents in the human body (Patrick et al., 1996). The radionuclides
such as 89Sr and 32P have also been successfully and effectively
utilized to provide palliative therapy to patients with multifocal
skeletal metastatic lesions in cases of breast and prostatic cancers.
Furthermore 90Y appears to be a potential beta-emitting radionu-
clide, which has been shown to offer attractive considerations for
being used in radioimmunotherapy (Stewart et al., 1988). Beta-
emitting radionuclide like 32P also ﬁnds application in infusional
brachytherapy (Hien Nguyen et al., 1997).
Markowicz and VanGriken (1984) proposed a new expression
for external Bremsstrahlung (EB) intensity (I) and modiﬁed atomic
number (Zmod) for a compound to taking into account the self
absorption of Bremsstrahlung and electron back scattering
I ¼ ConDE
Eg
Zmod

E0  Eg
 ½1 f  (1)
where En and E0 are emitted photon energy and incident electron
energy respectively and f is a function of E0, En and composition. In
above equation (1), Zmod is
Table 2
Composition of bone (in percentage).
Element Bone compact Bone cortical
H 6.398 4.723
C 27.800 14.43
N 2.700 4.199
O 41.001 44.609
Mg 0.200 0.270
P 0.700 10.497
S 0.200 0.315
Ca 14.700 20.993
Zn – 0.011
Table 1
Physical properties of b-ray emitters for radionuclide therapy.
Source Half-life (in days) Emax (MeV) EBr (MeV) Frequency of emission (fb)i/transformation
Y90 2.67 2.28 0.258 1
Pm143 13.60 0.93 0.102 1
Er169 9.40 0.35 0.038 1
Ti204 1387 0.77 0.084 1
Bi210 5.01 1.16 0.127 1
Sr89 50.5 1.49 0.163 1
Ca45 163 0.25 0.028 1
Table 3
Composition of dentin (in percentage).
Element Outer surface Middle surface Enamel dentin junction (EDJ)
C 38.590 36.280 37.050
O 32.590 34.210 34.510
Na 0.240 0.440 0.660
Mg 0.160 0.230 0.220
P 10.670 10.860 10.460
Cl 0.390 0.250 0.090
Ca 17.360 17.740 16.990
Table 5
Composition of soft tissue, lungs and skeleton (in percentage).
Element Skeleton Soft tissue Lungs
H 7.337 10.454 10.134
C 24.475 22.663 10.238
N 3.057 2.490 2.866
O 47.893 63.527 75.752
F 0.025 0.000 0.000
Na 0.326 0.112 0.184
Mg 0.112 0.013 0.007
Si 0.002 0.030 0.006
P 5.095 0.134 0.080
S 0.173 0.204 0.225
Cl 0.143 0.133 0.266
K 0.153 0.208 0.194
Ca 10.190 0.024 0.009
Table 6
Evaluated modiﬁed atomic number (Zmod) different portions of teeth.
Region Zmod
Enamel Outer surface 10.091
Enamel Middle 10.197
(EDJ) Enamel 10.053
(EDJ) Dentin 7.768
Dentin middle 8.508
Dentin inner surface 8.603
Bone cortical 11.697
Bone compact 9.197
Soft Tissue 7.064
Skeleton 8.001
Lung 6.585
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Pl
i
WiZ2i
Ai
Pl
i
WiZi
Ai
(2)
where Wi, Zi and Ai are weight fraction, atomic number and mass
number of ith element respectively. Shivaramu (1990) experimen-
tally measured the effective atomic number (Zeff) for compounds
from the measured EB yields and found that it agrees with Zmod.
The incorporated radio therapeutic beta-emitting nuclides
produces Bremsstrahlung radiation and could have different ener-
gies and intensities. Bremsstrahlung yield is a function of two
components namely Internal Bremsstrahlung and external
Bremsstrahlung. The intensity of external Bremsstrahlung largely
depends on the energy of the emitted beta particles and atomic
number of the surrounding matrix material. On the other handTable 4
Composition of enamel (in percentage).
Element Enamel dentin junction (EDJ)
C 59.000
O 30.670
Na 0.470
Mg 0.250
P 4.410
Cl –
Ca 5.190internal Bremsstrahlung component inherently depends on the
interaction of the emitted beta particle with the nucleus of the
source radionuclide itself. It can therefore be stated that the photon
characteristics of external Bremsstrahlung depend on the
surrounding matrix material whereas those of internal Brems-
strahlung would depend on the emission characteristics of radio-
nuclide. Bremsstrahlung produced in vivo is sufﬁcient for external
detection and imaging. The resulting external radiation hazardmay
therefore be some of concern, at least theoretically, and should be
systematically evaluated.Enamel middle surface Enamel inner surface
52.270 49.840
30.570 33.540
0.420 0.360
0.340 0.450
6.230 6.320
– –
9.150 9.500
Table 7
Speciﬁc bremsstrahlung constant for tooth & bone, GBr (in C=kg-cm2=MBq-h).
Radio nuclide Bone cortical Bone compact Enamel outer surface Enamel middle (EDJ) Enamel (EDJ) Dentin Dentin middle Dentin inner surface
Y90 2.93 103 2.3 103 2.53 103 2.55 103 2.46 104 1.94 104 2.13 103 2.15 103
Pm143 2.67 104 2.09 104 2.30 104 2.32 104 2.29 104 1.77 104 1.94 104 1.96 104
Er169 4.20 105 3.30 105 3.62 105 3.66 105 3.61 105 2.78 105 3.06 105 3.09 105
Ti204 7.66 107 6.02 107 6.61 107 6.68 106 6.58 106 5.08 106 5.57 107 5.64 107
Bi210 7.35 105 5.78 105 8.14 105 6.40 105 6.31 105 4.88 105 5.34 104 5.41 105
Sr89 2.09 107 1.65 107 1.81 107 1.83 107 1.80 107 1.39 107 1.52 107 1.54 107
Ca45 2.2 1012 1.7 1012 6.18 1012 1.97 1012 1.9 1012 1.4 1012 1.6 1012 1.6 1012
Table 8
Speciﬁc bremsstrahlung constant for soft tissue, lungs and skeleton, GBr (in
C=kg-cm2=MBq-h).
Radio nuclide Soft tissue Lungs Skeleton
Y90 1.77 103 1.65 103 2.00 103
Pm143 1.61 104 1.50 104 1.82 104
Er169 2.54 105 2.36 105 2.87 105
Ti204 4.62 107 4.31 107 5.24 107
Bi210 4.43 105 4.13 105 5.02 105
Sr89 1.26 107 1.18 107 1.43 107
Ca45 1.34 1012 1.25 1012 1.52 1012
Table 10
Probability of radiative energy loss of b-ray [(PBr)b] for soft tissue, lung and skeleton
(in keV).
Radio nuclide Soft tissue Lung Skeleton
Y90 5.36 5.00 6.08
Pm143 2.18 2.04 2.48
Er169 8.24 7.68 9.33
Ti204 1.81 1.69 2.05
Bi210 2.73 2.54 3.09
Sr89 3.05 3.27 3.97
Ca45 0.58 5.48 6.66
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The Bremsstrahlung dose equivalent from a radio activity-con-
taining patient in overall bone and tissue may be estimated using
(Zanzonico et al., 1999) following equations
DBrð1 m;NÞ ¼
34:6 Q0GBrT 0:25
ð100 cmÞ2
ð1 FBrÞ (3)
ðAreleaseÞBr¼
580
GBrTð1 FBrÞ
(4)
where DBr(1 m,N) is bremsstrahlung effective dose equivalent (in
cSv) at a distance of 1 m from the patient; (Arelease)Br is activity
(MBq) abovewhich patient should remain hospitalized on the basis
of the projected bremsstrahlung effective dose equivalent; T is
effective half-life of radionuclide; Q0 is initial activity (in MBq) in
the point source; VBr is average total body (TB)-to-TB absorption
fraction for bremsstrahlung of average energy EBr and GBr equals
‘‘speciﬁc bremsstrahlung constant’’(in C/kg-cm2/MBq-h) of the
radionuclide, that is the bremsstrahlung exposure rate (in C/Kg/h)
at a distance of 1 cm from a 1-MBq beta ray point source and it is
given by following equations
GBr ¼
Xn
i¼1

fb

i
h
ðPBrÞb
i
i
GBr
h
ðEBrÞb
i
i
(5)
h
ðPBrÞb
i
i
¼
Zmod
h
ðEmaxÞb
i
i
3000
(6)Table 9
Probability of radiative energy loss of b-ray [(PBr)b] for tooth & bone (in keV).
Radio nuclide Bone cortical Bone compact Enamel outer surface Enamel m
Y90 8.89 6.98 7.66 7.74
Pm143 3.62 2.85 3.12 3.16
Er169 1.36 1.07 1.17 1.18
Ti204 3.00 2.36 2.59 2.61
Bi210 4.52 3.55 3.90 3.94
Sr89 5.80 4.56 5.01 5.06
Ca45 0.97 0.76 0.84 0.87Br b i
max b ih
ðE Þ
i
¼ 0:11
h
ðE Þ
i
(7)
where [(PBr)b]i is probability of radiative loss by b-ray i; Zmod is
modiﬁed atomic number deﬁned for bremsstrahlung process given
by Markowicz et al. (1984). We have evaluated Zmod for bone
cortical, bone compact, tooth enamel, dentin, soft tissue, lungs and
skeleton using composition given in Tables 2–5 & Markowicz
formula (equation (2)). The evaluated values of Zmod are tabulated
in Table 6. (fb)i is frequency of emission(i.e., the number per nuclear
transformation) of b-ray i. [(EBr)b]i is mean energy (in MeV) of
bremsstrahlung for b-ray i emitted by a radionuclide. The spectrum,
which indicates the energy window equal to mean energy of
bremsstrahlung25% can be used for imaging without collimation.
[(Emax)b]I is max initial kinetic energy of b-ray i.
GBr½ðEBrÞbi is speciﬁc Bremsstrahlung constant (in C/kg-cm2/
MBq-h) of b-ray yielding Bremsstrahlung of mean energy [(EBr)b]i.
The estimation of the speciﬁc bremsstrahlung constant based on
the bremsstrahlung mean energy rather than the actual brems-
strahlung spectrum, is a gross approximation. The energy depen-
dent GBr½ðEBrÞbi corresponds to the conventional energy dependent
speciﬁc ray constant (Johns and Cunningham, 1969). The term
(1-FBr) is the fraction of photon energy of energy Eg, which is not
absorbed within the total body (TB), and is thus used to approxi-
mate the effect of shielding by the patient. A compilation of TB/TB
absorbed fraction as a function of photon energy and TB mass is
presented by Zanzonico et al. (1995) as adopted from Christy and
Eckerman (1987); absorbed fractions for photon energies and TBiddle (EDJ) Enamel (EDJ) Dentin Dentin middle Dentin inner surface
7.64 5.90 6.46 6.54
3.11 2.40 2.63 2.66
1.17 9.06 9.92 1.00
2.58 1.99 2.18 2.20
3.88 3.00 3.28 3.32
4.99 3.85 4.22 4.27
8.61 6.47 7.09 7.17
Table 11
Arelease in bone and tooth (in MBq).
Radio nuclide Bone cortical Bone compact Enamel outer surface Enamel middle (EDJ) Enamel (EDJ) Dentin Dentin middle Dentin inner surface
Y90 75495 96352 87787 87133 90247 11406 104118 80532
Pm143 164530 209374 190704 188738 191498 247872 222858 223652
Er169 162251 2063257 1879822 1862224 1890080 2229801 2229801 2208152
Ti204 544377 743373 677368 670371 680559 881512 803964 793986
Bi210 1624851 2066766 1466295 1866548 1893170 2447932 2237061 2208116
Sr89 56412159 71739594 65386331 64714602 65647296 84955324 77606633 76701892
Ca45 1799 109 2289 109 6474 109 2304 109 2057 109 2711 109 2475 109 2452 109
Table 12
Arelease in soft tissue, lungs and skeleton (in MBq).
Radio nuclide Soft tissue Lungs Skeleton
Y90 125459 110707 134578
Pm143 272544 240550 292303
Er169 2685555 2371634 2881415
Ti204 969281 854269 1038034
Bi210 2691125 2375404 2886321
Sr89 93470972 82528029 100201136
Ca45 2980 109 2631 109 3197 109
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the appropriate table entries.
The Speciﬁc bremsstrahlung constant (in C/kg-cm2/MBq-h) of
the radionuclide (GBr), Bremsstrahlung probability [(PBr)b] and the
activities, Arelease, of current and potential therapeutic radionu-
clides below which patients can be released from medical
conﬁnement in bone cortical, bone compact, different regions of
tooth enamel (enamel dentin junction (EDJ), enamel middle
surface, enamel inner surface), different regions of dentin (outer
surface, middle surface, enamel dentin junction (EDJ)), soft tissue,
lungs and skeleton for different therapeutic beta-emitting radio-
nuclides (Table 1) are calculated using equations (4)–(7) & tabu-
lated values of Zmod.3. Results and discussion
The activities, Arelease, of current and potential therapeutic
radionuclides below which patients can be released from medical
conﬁnement in Bone cortical, Bone compact, different regions of
tooth enamel (enamel dentin junction (EDJ), enamel middle
surface, enamel inner surface), different regions of dentin (outer
surface, middle surface, enamel dentin junction (EDJ)), soft tissue,
lungs and skeleton have been calculated for the 70 kg standardman
and it is given in Tables 11 and 12. These values have been
calculated assuming effective half-life of radionuclide, equals the
physical half-life and an exposure factor of 0.25 at a distance from
the patient of 1 m. Calculated Arelease values are found to be large:
on the order of thousands to millions of mega becquerels.
The evaluated values of GBr in different regions of bone, different
regions of tooth, soft tissue, lungs and skeleton are shown inTables 7
and 8 respectively. The speciﬁc Bremsstrahlung constant is the
exposure rate at a unit distance from a unit activity point source of
bremsstrahlung in air emitting one b-ray of the speciﬁedmaximum
energy (Emax)b per nuclear transformation and yielding brems-
strahlung of mean energy (EBr)b. The calculated probability of
a radiative energy loss (i.e., bremsstrahlung interaction) by each
b-ray is given in Tables 9 and10.
The estimated values of speciﬁc Bremsstrahlung constant (in
C=kg-cm2=MBq-h) of the radionuclide (GBr), Bremsstrahlungprobability [(PBr)b] and the activities, Arelease, of current and
potential therapeutic radionuclides below which patients can be
released from medical conﬁnement for different regions of bone
and tooth are greater than soft tissue. The proper localization is
possible in bone and tooth, because production of Bremsstrahlung
in different regions of teeth and bone are greater than the soft
tissue due to presence of high Z elements (especially calcium)
which leads to high modiﬁed atomic number (Zmod) which is the
function of Bremsstrahlung yield (according to equation (1))4. Conclusion
Proper localization and quantiﬁcation of incorporated beta
emitters in bone and tooth are possible, because Bremsstrahlung
production is greater in bone and tooth than soft tissue due to their
high modiﬁed atomic number (Zmod). For pure b-ray emitting
therapeutic nuclides, the activities requiring medical conﬁnement
are large: on the order of hundreds of thousand to millions of mega
Becquerels. But the patients receiving activities from radionuclides
are only of the order hundred mega Becquerels because of
probative radiation toxicity to the patient. Thus patients receiving
b-ray therapy do not have to be hospitalized for radiation
precautions.Acknowledgement
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